Share on StockTwits

Cryolife (NYSE:CRY) Chairman Steven G. Anderson unloaded 20,000 shares of Cryolife stock on the open market in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $10.08, for a total value of $201,600.00. Following the completion of the sale, the chairman now directly owns 1,346,333 shares in the company, valued at approximately $13,571,037. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Cryolife (NYSE:CRY) traded down 0.29% on Wednesday, hitting $10.15. 96,429 shares of the company’s stock traded hands. Cryolife has a one year low of $6.04 and a one year high of $12.14. The stock’s 50-day moving average is $9.93 and its 200-day moving average is $9.50. The company has a market cap of $283.4 million and a price-to-earnings ratio of 18.99.

Cryolife (NYSE:CRY) last released its earnings data on Thursday, July 24th. The company reported $0.08 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.05 by $0.03. The company had revenue of $34.69 million for the quarter, compared to the consensus estimate of $35.72 million. During the same quarter last year, the company posted $0.08 earnings per share. Cryolife’s revenue was up 3.6% compared to the same quarter last year. Analysts expect that Cryolife will post $0.20 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, September 19th. Shareholders of record on Friday, September 12th will be given a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date of this dividend is Wednesday, September 10th.

CryoLife, Inc (NYSE:CRY) is a biological medical device company.

Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.